Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 15:4:19.
doi: 10.1038/s41698-020-0122-1. eCollection 2020.

Machine learning approaches to drug response prediction: challenges and recent progress

Affiliations
Review

Machine learning approaches to drug response prediction: challenges and recent progress

George Adam et al. NPJ Precis Oncol. .

Abstract

Cancer is a leading cause of death worldwide. Identifying the best treatment using computational models to personalize drug response prediction holds great promise to improve patient's chances of successful recovery. Unfortunately, the computational task of predicting drug response is very challenging, partially due to the limitations of the available data and partially due to algorithmic shortcomings. The recent advances in deep learning may open a new chapter in the search for computational drug response prediction models and ultimately result in more accurate tools for therapy response. This review provides an overview of the computational challenges and advances in drug response prediction, and focuses on comparing the machine learning techniques to be of utmost practical use for clinicians and machine learning non-experts. The incorporation of new data modalities such as single-cell profiling, along with techniques that rapidly find effective drug combinations will likely be instrumental in improving cancer care.

Keywords: Combination drug therapy; High-throughput screening; Pharmacogenetics.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Graphical abstract.
Patient data are limited, so to predict drug response, much of the existing literature use model system data, e.g. immortalized cell lines and PDX. a Currently most patients in cancer are still treated in a one-size-fits-all manner according to the type (or subtype) of cancer they have. b There is a growing number of examples of personalizing monotherapy in practice, where depending on the mutations in the tumor, the patient can be prescribed a targeted drug. This approach is applicable to fewer than 20% of the patients. The computational contribution is to take a large number of model systems and patients, when available and construct a predictive model to identify the best drug for majority of the patients. c Due to tumor heterogeneity and acquired drug resistance, monotherapies may not be effective, there is currently a growing body of work predicting drug synergy and effective drug combinations. Originally these models were trained using bulk data, but more recently, single-cell data-based approaches are starting to show promise. The person symbol in the figure was obtained from dryicons.com. The black magnifying glass is courtesy of Stanislav Tischenko under the Creative Commons Attribution 3.0 License.

References

    1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 10.3322/caac.21492 (2018). - PubMed
    1. Cronin KA, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 2018;124:2785–2800. - PMC - PubMed
    1. Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J. Clin. Oncol. 2013;31:1803–1805. - PubMed
    1. Doherty M, Metcalfe T, Guardino E, Peters E, Ramage L. Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways. Ann. Oncol. 2016;27:1644–1646. - PubMed
    1. Heymach J, et al. Clinical Cancer Advances 2018: annual report on progress against cancer from the American Society of Clinical Oncology. J. Clin. Oncol. 2018;36:1020–1044. - PubMed